Showing results (1731-1740 of 1,873) with videos related to
Sort By:
Pageof 188
Nature Medicine|December 15, 2022
Dapagliflozin in heart failure with improved ejection fraction: a prespecified analysis of the DELIVER trialOrly Vardeny, James C Fang, Akshay S Desai, et al.International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|April 15, 2026
Positive Predictive Value of Respiratory Infection Diagnoses in The Danish National Patient Registry: a Post-hoc Validation Analysis of the DANFLU-1 TrialJacob Christensen, Niklas Dyrby Johansen, Katrine Feldballe Bernholm, et al.European Journal of Heart Failure|January 4, 2023
Efficacy of omecamtiv mecarbil in heart failure with reduced ejection fraction according to N-terminal pro-B-type natriuretic peptide level: insights from the GALACTIC-HF trialKieran F Docherty, John J V McMurray, Brian L Claggett, et al.European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology|January 29, 2026
Relative effectiveness of high-dose versus standard-dose influenza vaccine against hospitalizations and mortality according to Charlson Comorbidity Index: A post-hoc analysis of the DANFLU-1 randomized trialKatrine Feldballe Bernholm, Niklas Dyrby Johansen, Caroline Espersen, et al.JACC. Heart Failure|June 12, 2025
Efficacy and Safety of Finerenone in Heart Failure With Preserved Ejection Fraction: A FINE-HEART AnalysisJohn W Ostrominski, Gerasimos Filippatos, Brian L Claggett, et al.Diabetes Care|February 28, 2025
Efficacy and Safety of Finerenone in Type 2 Diabetes: A Pooled Analysis of Trials of Heart Failure and Chronic Kidney DiseaseJohn W Ostrominski, Brian L Claggett, Zi Michael Miao, et al.JAMA Cardiology|October 5, 2022
Association of Thoracic Aortic Aneurysm Size With Long-term Patient Outcomes: The KP-TAA StudyMatthew D Solomon, Thomas Leong, Sue Hee Sung, et al.Journal of the American College of Cardiology|August 30, 2022
Atrial Fibrillation and Dapagliflozin Efficacy in Patients With Preserved or Mildly Reduced Ejection FractionJawad H Butt, Toru Kondo, Pardeep S Jhund, et al.Journal of the American College of Cardiology|September 2, 2025
Anthropometric Measures, Cardiovascular Outcomes, and Treatment Effects of Finerenone in Cardiovascular-Kidney-Metabolic Disease: Pooled Participant-Level Analysis of Three Global TrialsJohn W Ostrominski, Josephine Harrington, Brian L Claggett, et al.JAMA Cardiology|June 18, 2025
Finerenone According to Frailty in Heart Failure: A Prespecified Analysis of the FINEARTS-HF Randomized Clinical TrialJawad H Butt, Pardeep S Jhund, Alasdair D Henderson, et al.Pageof 188